Related Experiment Video
Updated: Mar 16, 2026
Intracerebroventricular Treatment with Resiniferatoxin and Pain Tests in Mice
Published on: September 2, 2020
Resiniferatoxin: The Evolution of the "Molecular Scalpel" for Chronic Pain Relief
1Department of Clinical Studies-Philadelphia, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA. dottie@vet.upenn.edu.
Abstract:
Control of chronic pain is frequently inadequate or can be associated with debilitating side effects. Ablation of certain nociceptive neurons, while retaining all other sensory modalities and motor function, represents a new therapeutic approach to controlling severe pain while avoiding off-target side effects. transient receptor potential cation channel subfamily V member 1 (TRPV1) is a calcium permeable nonselective cation channel expressed on the peripheral and central terminals of small-diameter sensory neurons. Highly selective chemoablation of TRPV1-containing peripheral nerve endings, or the entire TRPV1-expressing neuron itself, can be used to control chronic pain. Administration of the potent TRPV1 agonist resiniferatoxin (RTX) to neuronal perikarya or nerve terminals induces calcium cytotoxicity and selective lesioning of the TRPV1-expressing nociceptive primary afferent population. This selective neuroablation has been coined "molecular neurosurgery" and has the advantage of sparing motor, proprioceptive, and other somatosensory functions that are so important for coordinated movement, performing activities of daily living, and maintaining quality of life. This review examines the mechanisms and preclinical data underlying the therapeutic use of RTX and examples of such use for the management of chronic pain in clinical veterinary and human pain states.
Insights
Resiniferatoxin (RTX) offers a novel approach to chronic pain management by selectively ablating pain-sensing neurons. This "molecular neurosurgery" spares essential functions, providing a safer alternative to existing treatments.
Area of Science:
- Neuroscience
- Pharmacology
- Pain Management
Background:
- Chronic pain control is often insufficient and linked to severe side effects.
- Targeting specific pain-sensing neurons offers a new therapeutic strategy.
- Transient receptor potential cation channel subfamily V member 1 (TRPV1) is crucial for pain signaling.
Purpose of the Study:
- To review the mechanisms and preclinical data for using resiniferatoxin (RTX) in chronic pain management.
- To explore RTX's potential for selective neuroablation of TRPV1-expressing neurons.
- To examine RTX's application in veterinary and human chronic pain conditions.
Main Methods:
- Selective chemoablation of TRPV1-expressing neurons using the TRPV1 agonist RTX.
- Induction of calcium cytotoxicity in TRPV1-containing nerve endings or neurons.
- Review of preclinical data and clinical examples in veterinary and human pain states.
Main Results:
- RTX administration leads to selective lesioning of TRPV1-expressing nociceptive primary afferents.
- This neuroablation spares motor, proprioceptive, and other somatosensory functions.
- Preclinical data support RTX as a viable therapeutic for chronic pain.
Conclusions:
- Selective ablation of TRPV1-expressing neurons via RTX represents a promising therapeutic approach for chronic pain.
- "Molecular neurosurgery" with RTX offers pain relief while preserving vital sensory and motor functions.
- Further research and clinical application of RTX are warranted for managing chronic pain in humans and animals.
